Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of SHR0302 for Induction and Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
2021-001940-86Phase 3Completed
- Sponsor
- Reistone Biopharma
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing SHR0302 arm with Placebo arm (2 arms). Primary endpoints: Clinical remission at Week 8 (Induction phase) and Long-term safety (Maintenance phase). Started Aug 2021; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-001940-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001940-86.